Vanda Pharmaceuticals
VNDA
99 hedge funds and large institutions have $348M invested in Vanda Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 14 closing their positions.
132% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 19
102% more call options, than puts
Call options by funds: $40.3M | Put options by funds: $20M
86% more capital invested
Capital invested by funds: $187M → $348M (+$161M)
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
13% more funds holding
Funds holding: 88 → 99 (+11)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$13.4M |
| 3 |
PA
Perceptive Advisors
New York
|
+$9.28M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$8.81M |
| 5 |
DM
Deerfield Management
New York
|
+$8.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$9.85M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$7.95M |
| 3 |
First Eagle Investment Management
New York
|
-$7.88M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$3.94M |
| 5 |
VM
VHCP Management
New York
|
-$3.17M |
VNDA Hedge Fund Activity: Q3 2013 in Review
99 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2013, worth a combined $348M — up 86% from $187M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new VNDA positions and 14 closed out — a net gain of 12 holders — while 44 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $25.3M. The largest seller was Consonance Capital Management, cutting an estimated $9.85M.
- 99 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2013, up from 88 in Q2 2013.
- Funds reported $348M of Vanda Pharmaceuticals stock for Q3 2013, up 86% quarter-over-quarter.
- 26 funds opened new Vanda Pharmaceuticals positions in Q3 2013 and 14 closed out, a net change of +12 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $25.3M added.
- The largest Vanda Pharmaceuticals seller in Q3 2013 was Consonance Capital Management, an estimated $9.85M sold.
Based on aggregated 13F filings for Q3 2013.